News

February 2, 2025

Affibody regains worldwide rights to izokibep

Stockholm, Sweden, February 2, 2025. Affibody today announced that the company will regain all rights to izokibep. In 2021, Affibody and ACELYRIN, INC. entered into a license and collaboration...

Read more

News

January 15, 2025

Additional data from Affibody’s HER2 radiopharmaceutical program presented at PepTalk

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more

News

January 10, 2025

Affibody regains rights in selected Asian countries to izokibep

Stockholm, Sweden, January 10, 2025. Affibody today announced that the company has regained rights to izokibep in selected Asian countries. In 2020, Affibody and Inmagene Biopharmaceuticals entered into a...

Read more

News

January 7, 2025

Affibody’s Nomination Committee for the 2025 Annual General Meeting

Stockholm, Sweden, January 7, 2025. Affibody Medical AB (publ) today announced the composition of the Nomination Committee for the 2025 Annual General Meeting (AGM) to be held on May...

Read more

News

October 20, 2024

Data demonstrating pre-clinical efficacy and safety of Affibody’s radio-therapeutic anti-HER2 agent ABY-271 presented at EANM annual congress

Affibody AB (“Affibody”) announces presentation of data from IND enabling preclinical studies with the radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2 expressing metastatic disease. The data will be presented...

Read more

News

September 19, 2024

Positive Results from Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Presented at EADV 2024 in Late-Breaking Session

Stockholm, Sweden, September 19, 2024. Affibody today announced that the positive results from a Phase 3 trial of izokibep in hidradenitis suppurativa will be presented at the 2024 European...

Read more

News

June 5, 2024

Positive 16-week Data From Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis Presented at EULAR 2024 Late Breaking Session

Stockholm, Sweden, June 5, 2024. Affibody today announced that positive 16-week data from a global Phase 2b/3 trial of izokibep in psoriatic arthritis (PsA) will be presented at the...

Read more

News

April 18, 2024

NOTICE OF ANNUAL GENERAL MEETING IN AFFIBODY MEDICAL AB (PUBL)

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby invited to attend the annual general meeting of the shareholders on Thursday...

Read more

News

March 19, 2024

Change in Affibody’s Nomination Committee for the 2024 Annual General Meeting

Stockholm, Sweden, March 19, 2024. Affibody Medical AB (publ) today announced a change of the composition of the Nomination Committee for the 2024 Annual General Meeting (AGM) to be...

Read more